Brokerages Set Avalo Therapeutics, Inc. (NASDAQ:AVTX) Price Target at $34.88

Avalo Therapeutics, Inc. (NASDAQ:AVTX) has earned an average recommendation of “Moderate Buy” from the eleven research firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, nine have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $34.8750.

Several brokerages have commented on AVTX. Guggenheim initiated coverage on Avalo Therapeutics in a research note on Monday, February 2nd. They issued a “buy” rating and a $50.00 target price for the company. HC Wainwright reissued a “buy” rating and issued a $25.00 price target on shares of Avalo Therapeutics in a report on Thursday, January 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Avalo Therapeutics in a research report on Friday, January 9th. Finally, Mizuho raised shares of Avalo Therapeutics to a “strong-buy” rating in a report on Thursday, December 18th.

Avalo Therapeutics Price Performance

Shares of NASDAQ:AVTX opened at $14.26 on Friday. Avalo Therapeutics has a 1 year low of $3.39 and a 1 year high of $20.72. The company has a market capitalization of $263.95 million, a PE ratio of -2.66 and a beta of 0.88. The business has a fifty day moving average price of $16.74 and a two-hundred day moving average price of $14.49.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Orbimed Advisors LLC raised its position in Avalo Therapeutics by 39.5% in the 3rd quarter. Orbimed Advisors LLC now owns 1,349,300 shares of the company’s stock worth $17,150,000 after purchasing an additional 382,300 shares during the period. Nantahala Capital Management LLC grew its stake in shares of Avalo Therapeutics by 24.1% during the third quarter. Nantahala Capital Management LLC now owns 1,235,000 shares of the company’s stock valued at $15,697,000 after buying an additional 240,000 shares during the last quarter. Affinity Asset Advisors LLC grew its stake in shares of Avalo Therapeutics by 4.5% during the fourth quarter. Affinity Asset Advisors LLC now owns 1,051,054 shares of the company’s stock valued at $19,087,000 after buying an additional 44,837 shares during the last quarter. Caligan Partners LP purchased a new position in shares of Avalo Therapeutics in the third quarter worth about $10,592,000. Finally, Balyasny Asset Management L.P. bought a new stake in shares of Avalo Therapeutics in the 3rd quarter valued at about $10,390,000. Institutional investors own 87.06% of the company’s stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.